• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

    4/3/25 4:05:00 PM ET
    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $ABCL alert in real time by email

    AbCellera (NASDAQ:ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

    A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call.

    About AbCellera Biologics Inc.

    AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250403307038/en/

    Media: Tiffany Chiu; [email protected], +1(236)521-6774

    Business Development: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005

    Investor Relations: Peter Ahn; [email protected], +1(778)729-9116

    Get the next $ABCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCL

    DatePrice TargetRatingAnalyst
    8/20/2024Buy → Hold
    The Benchmark Company
    2/22/2024$9.00Hold → Buy
    The Benchmark Company
    12/5/2023$6.00Overweight
    KeyBanc Capital Markets
    11/6/2023Buy → Hold
    The Benchmark Company
    10/13/2023$20.00Overweight
    Piper Sandler
    2/28/2023Outperform
    Cowen
    12/15/2022$30.00Buy
    Goldman
    11/16/2022$29.00Buy
    Truist
    More analyst ratings